Edition:
India

Ironwood And Allergan Report Positive Topline Data From Phase Iiib Trial Of Linzess


Wednesday, 19 Jun 2019 

June 18 (Reuters) - Allergan plc ::IRONWOOD AND ALLERGAN REPORT POSITIVE TOPLINE DATA FROM PHASE IIIB TRIAL OF LINZESS® (LINACLOTIDE) IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C).ALLERGAN PLC - PHASE IIIB STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE.ALLERGAN PLC - PHASE IIIB STUDY DEMONSTRATED LINACLOTIDE IMPROVED OVERALL ABDOMINAL SYMPTOMS OF BLOATING, PAIN AND DISCOMFORT IN ADULTS WITH IBS-C.ALLERGAN PLC - LINACLOTIDE WAS WELL-TOLERATED IN THIS PHASE IIIB STUDY, WITH MOST COMMONLY REPORTED ADVERSE EVENT BEING DIARRHEA.